Hepatitis E: New Drug Target Identified

Researchers have identified bemnifosbuvir as a promising compound in the fight against hepatitis E virus (HEV), a disease that causes approximately 70,000 deaths globally each year.

The discovery, detailed in reports from March 20, 2026, marks a significant step forward in addressing a virus for which there is currently no specific vaccine or drug treatment. Bemnifosbuvir has demonstrated effective antiviral activity against HEV, offering a potential pathway toward targeted therapies.

Hepatitis E, a viral infection affecting the liver, can lead to jaundice, fatigue, and abdominal pain. Severe cases can result in acute liver failure, posing a substantial risk to patients. The lack of dedicated treatment options has complicated managing the disease, underscoring the need for therapeutic interventions.

While research into potential treatments has been ongoing, a team at Ruhr-University Bochum, Germany, previously identified the compound K11777 as a potential agent against hepatitis E in May 2024. K11777 works by preventing host cells from assisting the virus in escaping its shell, thereby inhibiting infection. This compound is already undergoing clinical trials for other viruses, including SARS-CoV-2, according to lead author Mara Klöhn.

The recent identification of bemnifosbuvir builds on this research, offering another potential avenue for treatment. Researchers are utilizing human liver-derived organoids to study virus-host interactions and to test the efficacy of antiviral drugs, including bemnifosbuvir.

Despite the promising developments, further research is needed to determine the clinical viability of both bemnifosbuvir and K11777 as treatments for hepatitis E. Clinical trials are planned to assess the safety and efficacy of these compounds.